Zivex-LS Syrup is a combination pharmaceutical formulation containing Levosalbutamol (1mg/5ml), Ambroxol (30mg/5ml), and Guaifenesin (50mg/5ml), designed to provide comprehensive relief in respiratory conditions characterized by bronchospasm, mucus hypersecretion, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscles, thereby improving airflow and alleviating symptoms of bronchoconstriction commonly seen in asthma and chronic obstructive pulmonary disease (COPD). Ambroxol serves as a mucolytic agent, enhancing the clearance of mucus by breaking down mucopolysaccharide fibers, facilitating expectoration and reducing airway obstruction. Guaifenesin, an expectorant, promotes the thinning and loosening of mucus in the airways, further aiding in effective cough and sputum clearance. The synergistic action of these active ingredients makes Zivex-LS Syrup effective in managing acute and chronic respiratory disorders such as bronchitis, asthma exacerbations, and other conditions with excessive mucus production and airway constriction. It is indicated for patients requiring bronchodilation alongside mucolytic and expectorant therapy to improve respiratory function and comfort. Administration should follow prescribed dosage guidelines, with caution advised in patients with hypersensitivity to any component or underlying cardiac conditions.